Sanguine Leukopaks **Disease State & Healthy Donors**

High-quality, high-volume apheresis products and donor data from our extensive network of research-ready study participants



COMPREHENSIVE **DONOR DATA**

Confidently choose patients with confirmed disease diagnosis and healthy matched controls:

RECALLABLE DONORS

Strong relationships with a diverse, nationwide network of 70,000+ donors and 100+ patient advocacy groups


CONSISTENCY

Obtain up to 10 billion immune cells fresh or cryopreserved from one individual in a single donation



Strict adherence to standards and protocols ensures high cell viability & recovery, documented in a certificate of analysis

- Annotated medical records
- Study-specific questionnaires
- Infectious disease status
- HLA typing class 1 & 2
- Complete blood count (CBC)
- Demographics



Apheresis-separated lymphocytes and monocytes (leukopaks) collected from the same donor provide a reliable and consistent source of peripheral blood mononuclear cells (PBMCs) for biomarker, immunology, autologous, and allogeneic cell therapy research.^{1,2} Obtaining billions of PBMCs in a single donation from recallable individuals with annotated medical data can accelerate the development of diverse therapy programs, from discovery to manufacturing.

To facilitate translational, clinical, and product manufacturing investigations, Sanguine Biosciences offers fresh and cryopreserved leukapheresis products for Research Use Only. Leukopaks are collected from consenting donors at qualified apheresis clinics under an IRB-approved protocol. Upon request, PBMCs or lymphocytes can be further isolated into 25 or 100 million cell aliquots.

Use Leukopaks for:



Assay validation





Š., Cell & Gene Therapy

Study participants are selected from our growing nationwide network of 70,000+ research-ready and recallable patients across multiple disease states, including autoimmune, metabolic, and genetic conditions. Identify matched controls among our extensive healthy donor database while limiting donor variability for assay validation and process development initiatives.

You can screen for donors with distinct biomarker signatures before committing to a large-volume leukopak collection:

- Disease-state leukopaks: design an in-home, prospective study and recall specific donors.
- Healthy leukopaks: screen isolated PBMCs from inventory collections to obtain cryopreserved PBMC aliquots of the entire donation (≥4 billion cells) or recall specific donors for a fresh collection.

Take advantage of additional services:

Mononuclear cell isolation (PBMCs, T,

l≡qJ

200+ additional CLIA-certified B, and/or NK cells) diagnostic tests Prospective collection of additional samples from the same donor

© Sanguine 2023 | Rev: LEUK-OPR-23-05

₿ø

Sanguine

Disease states				
Crohn's Disease	Asthma	Gout	Psoriasis	
Ulcerative Colitis	Atopic Dermatitis	Hashimoto's Disease	Pulmonary Arterial Hypertension	
Systemic Lupus Erythematosus	CIDP	Hepatitis C	Scleroderma	
Rheumatoid Arthritis	Chronic Kidney Disease	Hidradenitis Suppurativa	Sickle Cell Trait	
Multiple Sclerosis	COPD	Hypercholesterolemia	Sjogren's Syndrome	
Celiac Disease	Cystic Fibrosis	Hypertension	Vitiligo	
HIV	Diabetes Type 1	Hypothyroidism	*Additional conditions being	
Hepatitis B	Diabetes Type 2	Myasthenia Gravis	added, please inquire	
Arthritis	Fibromyalgia	Osteoarthritis	for updates	

Use	Research Use Only (RUO)		
Collection method	Leukapheresis at qualified apheresis sites nationwide		
Cell viability measurement	Fluorescent-based cell counting (disease state and cryopreserved healthy)		
Compliance validation	IRB approved protocol and HIPAA complianceRecords tracked via clinical quality management system		
	Fresh	Cryopreserved	
Collection size	Full (8-10 billion cells)	Full (8–10 billion cells) Half (4–6 billion cells)	
Preservation and delivery	 Shipped same day for overnight delivery 	 Same-day cryopreservation in CryoStor CS-10 serum-free media 	
	 Same-day delivery available in select geographies 	 Controlled-rate freezing with long-term storage in LN2 	
		 Shipped on dry ice overnight 	

Example Publications using **Disease State and Healthy Donor PBMCs from Sanguine**:

Science Translational Medicine

Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice

PBMCs from a patient with type 1 diabetes were used to engraft an autologous, humanized autoimmune diabetes mouse model in testing a hypoimmune beta-cell replacement therapy.³ frontiers in Immunology

Signaling Through gp130 Compromises Suppressive Function in Human FOXP3+ Regulatory T Cells Healthy donor PBMCs were used in ellucidating how gp130 expression reduces suppressive Treg function, a potentially novel therapeutic avenue for tuning Tregs.⁴

Search our network of 70,000+ study participants



Discuss a study design

¹Mackensen A et al. (2022) <u>Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus</u>. *Nat. Med.* 28: 2124-2132. ²Rodell CB, Koch PD, Weissleder R. (2019) <u>Screening for new macrophage therapeutics</u>. Theranostics. 9(25): 7714-7729. ³Hu X et al. (2023) Human hypoimmune primary paperentic islets avoid rejection and autoimmunity and alleviate diabetes in allogenei

³Hu X et al. (2023) <u>Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice.</u> *Sci Transl Med.* 15: eadg5794.

⁴Dhuban et al. (2019) Signaling Through gp130 Compromises Suppressive Function in Human FOXP3+ Regulatory T Cells. Front Immunol 10:1532.

© Sanguine 2023 | Rev: LEUK-OPR-23-05

